Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung CancerGlobeNewsWire • 09/26/23
Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/06/23
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/10/23
Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth ConferenceGlobeNewsWire • 08/02/23
Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024GlobeNewsWire • 06/13/23
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of DirectorsGlobeNewsWire • 06/08/23
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare ConferenceGlobeNewsWire • 06/05/23
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual MeetingGlobeNewsWire • 05/19/23
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/11/23
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung CancerGlobeNewsWire • 04/17/23
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/30/23
Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology DayGlobeNewsWire • 02/01/23
Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with CancerGlobeNewsWire • 12/06/22
Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual MeetingGlobeNewsWire • 11/18/22
Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade GliomaGlobeNewsWire • 11/11/22
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/10/22
Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNOGlobeNewsWire • 11/07/22
Candel Therapeutics Partners with the University of Pennsylvania's Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor ModelsGlobeNewsWire • 10/26/22
Candel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in GliomaGlobeNewsWire • 09/15/22